Moreover, high plasma hRNase5/ANG level of pancreatic cancer patients can predict better treatment response to erlotinib with the potential to serve as a serum biomarker to stratify patients for erlotinib treatment [46]. The gene discussed is ANG; the disease is pancreatic neoplasm.